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We have previously reported a large Danish pedigree with
autosomal dominant frontotemporal dementia (FTD) linked
to chromosome 3 (FTD3). Here we identify a mutation in
CHMP2B, encoding a component of the endosomal ESCRTIII
complex, and show that it results in aberrant mRNA splicing in
tissue samples from affected members of this family. We also
describe an additional missense mutation in an unrelated
individual with FTD. Aberration in the endosomal ESCRTIII
complex may result in FTD and neurodegenerative disease.
FTD is the second most common cause of presenile dementia,
accounting for up to 20% of cases1. FTD is genetically heterogeneous,
with associated loci identified on chromosomes 9 (ref. 2) and 17 (ref.
3). We previously reported linkage of a dominant FTD phenotype
segregating within a large Danish family to a pericentromeric region of
12 cM on chromosome 3 (FTD3). The brains of individuals with
FTD3 have no distinctive neuropathological features. They show
global cortical and central atrophy, but no b-amyloid deposits are
found and immunostaining for tau is not suggestive of a tauopathy4,5.
Onset of dementia is typically in the late 50s and is initially
characterized by behavioral and personality changes including apathy,
restlessness, disinhibition and hyperorality, progressing to stereotyped
behaviors, non-fluent aphasia, mutism and dystonia, with a marked
lack of insight. The family spans six generations with over 450 known
members (Supplementary Fig. 1 online).
Markers within the non-recombinant region were used to genotype
family members, and a common haplotype spanning an estimated
15.5-Mb interval defined by markers D3S3581 and D3S3690 was seen
in all affected individuals (Supplementary Fig. 2 and Supplementary
Methods online). We sequenced several candidate genes from
within the critical region, selected on the basis of likely function
and pattern of expression, and found only one mutation, a G-to-C
transition in the acceptor splice site of exon 6 in CHMP2B
(charged multivesicular body protein 2B, also known as chromatin-
modifying protein 2B) (Supplementary Fig. 3 online), which encodes
a component of the ESCRTIII complex6. This change segregated in all
11 affected family members screened and was not seen in 14
unaffected family members, 120 Centre d’E´tude du Polymorphisme
Humain (CEPH) control samples or 100 control DNA samples from
unaffected Danes. This mutation alters the highly conserved splice-site
consensus sequence and is predicted to disrupt processing of
CHMP2B mRNA.
We carried out RT-PCR amplification of CHMP2B on total RNA
extracted from brain samples and lymphoblast cell lines from affected
and unaffected family members and unrelated controls. Two abundant
transcripts not previously identified were found in samples from
affected individuals (Fig. 1a). Subcloning and sequence analysis of
these aberrant amplification products showed either inclusion of the
201-bp intronic sequence spanning exons 5 and 6, referred to as
CHMP2BIntron5, or a short deletion resulting from the use of a cryptic
splice site mapping 10 bp from the 5¢ end of exon 6, CHMP2BD10
(Fig. 1b). We observed an additional aberrant amplification product
in samples from affected individuals but were unable to subclone or
sequence it. Further analysis suggested that this band was a hetero-
duplex formed between wild-type and CHMP2BIntron5 amplification
products (data not shown).
To investigate whether the CHMP2B locus has a broader involve-
ment in FTD, we sequenced all exons and splice sites (see Supplemen-
tary Table 1 online) from the genomic DNA of 400 unrelated
European individuals with an FTD phenotype, of whom 89 had a
family history of the condition. This sequence analysis identified a
G442T substitution in exon 5, in one affected individual, that was not
detected in 100 normal individuals from the CEPH dataset (Supple-
mentary Fig. 3 online). This individual had dementia (age of onset 69
years) involving progressive naming and comprehension deficits along
with mild disinhibition and irritability. Formal neuropsychometry
confirmed the classic features of semantic dementia. Magnetic reso-
nance imaging revealed mild bifrontal and marked left temporal lobe
atrophy, and single-photon-emission computed tomography (SPECT)
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showed reduced perfusion with the same distribution. There was no
clear family history of neurodegenerative disease.
Human CHMP2B (CHMP2.5, CGI-84) is a protein of 213 amino
acids containing predicted coiled-coil, Snf-7 and acidic C-terminal
domains. The yeast ortholog, Vps2, was initially identified in a large-
scale systematic mutagenesis screen for unusual vacuolar protein
sorting (vps) phenotypes in Saccharomyces cerevisae7. Disruption of
the VPS2 (DID4) gene in yeast results in the formation of dysmorphic
hybrid vacuole-endosome organelles termed class E structures. Fifteen
vps mutants displaying class E structures have been described, the
majority of which are components of ESCRT complexes (endosomal
secretory complex required for transport) I, II or III7,8.
Yeast Vps2 is part of the ESCRTIII complex, which is formed
transiently on the limiting membrane of multivesicular bodies
(MVBs) after recruitment of component peptides including Vps2,
Vps24, Snf7 and Vps20 from the cytosol7. Dysfunction of these
components or of Vps4, an ATPase required for active dissociation
of the ESCRTIII complex, results in an inability of the MVBs to
internalize membrane-bound cargo7,9.
Northern-blot analysis showed that wild-type CHMP2B is ex-
pressed in multiple human tissues and in all major regions of
the brain, including the frontal and temporal lobes (Fig. 1c). The
most abundant transcript is approximately 2.4 kb, supported by
a GenBank predicted CHMP2B sequence of 2.41 kb. In addition,
our northern-blot analysis showed transcripts of approximately 1.9 kb
and 1.35 kb suggestive of alternative 5¢ and 3¢ untranslated regions
(data not shown). In situ hybridization of mouse brain revealed
widespread expression in all neuronal populations (Fig. 1d). We
observed relatively enhanced expression in the hippocampus, frontal
and temporal lobes and in both granule and Purkinje cells of the
cerebellum. No astrocytes or oligodendrocytes were labeled. This gene
is expressed in numerous tissues that show no known disease
phenotype, which mirrors findings in other neurodegenerative disease
and suggests that there are other cellular processes underlying the
mechanism of neurodegeneration.
Predicted translation of the three mutant transcripts indicates a 36-
amino-acid truncation affecting predicted a-helical and Snf-7
domains of the protein’s acidic C terminus for CHMP2BIntron5, a
replacement of the same region with an abnormal 29-amino-acid C
terminus for CHMP2BD10, and a missense D148Y substitution in the
Snf-7 domain for CHMP2BG442T. The amino acid at this position is
highly conserved in CHMP2B orthologs (Supplementary Fig. 4).
We sought direct evidence for the pathogenicity of mutant
CHMP2BD10 or CHMP2BIntron5 by investigating their effects on the
late endosome. Specifically, we transfected rat PC12 cells with con-
structs expressing full-length recombinant CHMP2B isoforms under a
constitutive cytomegalovirus promoter. After 48 h, cells transfected with
the wild-type CHMP2B construct showed a generalized cytosolic
expression pattern for the recombinant protein (Fig. 2a). Cells expres-
sing mutant CHMP2BD10 or CHMP2BIntron5 protein had aberrant
structures dispersed throughout the cytosol and showed isoform-
specific staining patterns. We observed similar results with U2OS cells
(data not shown). CHMP2BD10-expressing cells showed widely distrib-
uted small punctate bodies, whereas those expressing CHMP2BIntron5
had fewer aberrant bodies of a greater relative size (Fig. 2b,c). Confocal
analysis of these structures in cells expressing CHMP2BIntron5 showed
that the mutant protein accumulated on the outer membrane of the
larger aberrant bodies, with no apparent lumenal staining (Fig. 2c,d).
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Figure 1 Genomic and transcriptional defects of CHMP2B. (a) RT-PCR across exons 4 and 6 identified two aberrant products in cDNA from lymphoblast cell
lines (Lym.) and brain in affected individuals. Neg., negative control. (b) CHMP2B genomic structure, position of mutation and resulting transcripts.
Transcript CHMP2BIntron5 retains intron 5. Transcript CHMP2BD10 uses a cryptic splice site within exon 6. cDNA lengths are based on mutant ORF
sequences and GenBank sequence BC001553.1. (c) Northern blots containing total RNA from human adult brain regions and other tissues were hybridized
with a CHMP2B cDNA probe (or human b-actin as a control; below). (d) In situ hybridization of mouse Chmp2b sense and antisense riboprobes on sequential
sagittal sections of mouse brain. Images below show higher magnification of cortical, hippocampal and cerebellar subregions displaying prominent staining.
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To investigate whether these aberrant bodies represent dysmorphic
endosomes, cells expressing CHMP2B isoforms were pulse-chase
labeled with fluorescent dextran, an exogenous marker of the endo-
somal pathway10. Dextran accumulated in the lumen of the larger
aberrant bodies of cells expressing CHMP2BIntron5 (Fig. 2d–f), but did
not always accumulate in or associate with the smaller punctate bodies
found in some cells expressing CHMP2BIntron5 or CHMP2BD10
(Supplementary Fig. 5). Further analysis using antibodies to CD63,
a specific marker of late endosomal and lysosomal organelles11,
showed colocalization of the mutant protein and CD63 on the
periphery of the larger aberrant structures found in cells expressing
CHMP2BIntron5 (Fig. 2j–l). In contrast, smaller aberrant bodies from
CHMP2BIntron5- and CHMP2BD10-expressing cells colocalized only
partially (Supplementary Fig. 5). Partial colocalization was also seen
in CHMP2BWild-type- expressing cells (Fig. 2m–o).
Here we provide evidence that mutation in the CHMP2B gene,
which may cause a primary defect in the ESCRTIII complex, leads to
neurodegenerative disease. We have shown that the mutation found in
the large Danish kindred with FTD disrupts CHMP2B localization in
cell culture and results in the formation of dysmorphic organelles of
the late endosomal pathway. Notably, similar aberrant endosomal
structures are seen in conjunction with ectopic overexpression of
ALSIN, a gene associated with a recessive form of motor neuron
disease12. In addition, spastin, a protein mutant in hereditary spastic
paraplegia, another form of motor neuron disease, interacts directly
with the ESCRTIII component CHMP1B13. Histopathological
abnormalities are also seen in endosomes in preclinical stages of
neuropathological disease such as Alzheimer disease, Neimann-Pick
type C disease and Down syndrome14.
FTD3 is, to date, unique to one Danish kindred and we have not yet
seen cosegregation of CHMP2B mutations in other FTD kindreds to
strengthen the evidence for their causality; it remains possible that an
undetected coding or non-coding change elsewhere in the 15.5-Mb
disease haplotype region is responsible. However, the two mutations
described here lie in extremely highly conserved domains and are
predicted to perturb protein function substantially. Furthermore,
expression of mutant CHMP2B in cell culture results in a phenotype
consistent with the known biology of its yeast homolog Vps2.
Attempts to model FTD3 in transgenic mice are underway. There is
increasing evidence for disruption of endosomal trafficking in neuro-
degeneration, and together with the considerable phenotypic overlap
that exists between FTD and other neurodegenerative diseases15, this
study should encourage a search for mutations in genes encoding
proteins of the ESCRT I, II and III complexes in other neurological
conditions in which a defined genetic cause has not yet been identified.
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Figure 2 Overexpression of mutant CHMP2B isoforms produces an aberrant
phenotype. Undifferentiated PC12 cells were transfected with expression
constructs encoding recombinant protein c-Myc–CHMP2B, c-Myc–
CHMP2BD10 or c-Myc–CHMP2BIntron5 and stained with FITC-conjugated
antibody to c-Myc. (a–c) Confocal analysis showed that wild-type CHMP2B
(a) resulted in generalized cytoplasmic expression, whereas the aberrant
isoforms CHMP2BD10 (b) and CHMP2BIntron5 (c) resulted in cytoplasmic
punctate bodies of variable size. The percentage of c-Myc–positive cells
containing punctate aberrant bodies of variable size is indicated for each
CHMP2B isoform. (d–i) The large aberrant bodies of CHMP2BIntron5
sequestered an endocytic tracer (d–f), in contrast to wild-type CHMP2B
(g–i). After transfection, PC12 cells were fixed and stained with antibody to
c-Myc to show expression of CHMP2BIntron5 and wild-type CHMP2B (d,g).
Before fixation, cells were incubated in fluorescently labeled dextran (e,h).
The images were merged to assess colocalization (f,i). (j–o) The aberrant
bodies of CHMP2BIntron5 were shown to colocalize with CD63 (j–l), in
contrast to wild-type CHMP2B (m–o). After transfection, cells were doubly
stained with antibodies to c-Myc (j,m) and to CD63 (k,n) and the images
merged to assess colocalization (l,o). Bar, 5 mm.
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